Lineage Cell Therapeutics, Inc. (LCTX) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Lineage Cell Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Biological Products, (No Diagnostic Substances)
Prev close 1.06 · gapped above the open, then crossed back over prior close. High/low 1.10 at 5:00 am ET, 1.03 at 11:45 am ET.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
5 readings, 3 filed under bull and 2 under bear. Every figure is ours; the model chose the side.
the bull case· 3
13
disclosed supplier and customer ties in SEC filings
sec filingsedgar129
managers reporting a position in thirteen F filings
13fJun 30 '26+14.05%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26the bear case· 2
7
managers whose positions together make up four fifths of reported value
13fJun 30 '268 of 22
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '26The model filed each reading under bull or bear and wrote its caption; a caption carrying a digit is replaced by our own phrase, so every figure on this zone is ours. Built Sep 16 '26 against the Nov 9 '26 report; rebuilt when that date rolls. Not a forecast, not advice.
Lineage Cell Therapeutics, Inc. has no measured co-movers clearing our correlation floor, so only its SEC classification is shown.
SIC 2836, Biological Products, (No Diagnostic Substances), from each company's own filings. Largest first.
129 managers report a position worth $152.7M between them, and 7 of them hold 80% of it.
tall tick = annual report · 1 on record
LCTX (Lineage Cell Therapeutics, Inc.) has 9 disclosed suppliers and 4 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.